Inozyme Pharma Insiders Bank 37% Return From Rock Bottom Secondary Offering
Inozyme Pharma (NASDAQ:INZY) has been experiencing high levels of insider accumulation, with five net insiders acquiring shares over the last 90 days. Insider accumulation at the biotech company that develops therapies for rare mineralization disorders is bullish, with a Fintel score of 98.83, the seventh highest score when screened against 14,499 other stocks. Insiders increased their holdings, buying during a $73 min secondary offering in April at $3.69 per share. The shares made the offering’s buyers a hefty 37% return that easily topped the Nasdaq’s 10% slide. Q1 2022 hedge fund letters, c...